{"id":6,"slug":"6-epitalon-ala-1-d-ala-substitution-n-terminal-d-amino-acid","title":"Epitalon D-Ala1 N-terminal protection to extend plasma half-life","status":"DISCARDED","fold_verdict":"DISCARDED","discard_reason":null,"peptide":{"name":"Epitalon","class":"LONGEVITY","sequence":"AEDG","modified_sequence":"(D-Ala)-EDG","modification_description":"Ala-1 → D-Ala substitution (N-terminal D-amino acid)"},"target":{"protein":"Telomerase reverse transcriptase","uniprot_id":"O14746","chembl_id":"CHEMBL2916","gene_symbol":"TERT"},"rationale":{"hypothesis":"We hypothesize that substituting the N-terminal L-Ala with D-Ala will protect Epitalon from rapid aminopeptidase-mediated degradation in plasma while preserving the compact AEDG pharmacophore responsible for its reported telomerase-modulating activity. Because the tetrapeptide is extremely short (4 residues) and currently has a half-life on the order of minutes, even a modest gain in proteolytic stability should meaningfully extend systemic exposure for longevity dosing protocols.","rationale":"Aminopeptidases (e.g., APN/CD13) cleave L-configured N-terminal residues but tolerate D-amino acids very poorly, a strategy validated in many short therapeutic peptides (e.g., DSIP, GHK analogs, gonadorelin). D-Ala retains the same small methyl side chain as L-Ala, so steric and hydrophobic contributions to any TERT-interacting surface should be largely preserved; only backbone chirality at position 1 changes. Given Epitalon's flexible, largely unstructured nature in solution, the backbone perturbation is unlikely to disrupt a defined fold but should block exopeptidase recognition.","predicted_outcome":"Structure prediction should yield an essentially superimposable extended/loop conformation versus wild-type AEDG with comparable (low-to-moderate) pLDDT, since the peptide is intrinsically flexible. We expect no new secondary structure and minimal RMSD change in the side-chain placements of Glu-2, Asp-3, and Gly-4, supporting the interpretation that activity-relevant geometry is retained while proteolytic vulnerability is reduced.","mechanism_class":null,"biohacker_use":null},"confidence":{"plddt":0.33971840143203735,"ptm":0.2047090232372284,"iptm":0.1640138328075409,"chai_agreement":null,"chai1_gated_decision":"SKIPPED_LOW_CONFIDENCE","binding_probability":null,"binding_pic50":null,"predicted_binding_change":null},"profile":{"aggregation_propensity":0.0,"stability_score":0.4,"bbb_penetration_score":0.407,"half_life_estimate":"short (~15–45 minutes)"},"narrative":{"tldr":"DISTILLATION №6 explores a D-Ala1 substitution on the tetrapeptide Epitalon (AEDG), intended to block aminopeptidase-mediated N-terminal cleavage and extend plasma half-life. Boltz-2 returned extremely low confidence metrics (pLDDT 0.34, pTM 0.20, ipTM 0.16), consistent with a fully disordered four-residue chain that resists meaningful structural prediction. The DISCARDED verdict reflects a tool limitation rather than a biological failure: the modification hypothesis remains pharmacologically coherent, but in silico structure prediction cannot adjudicate it for a peptide this short. The negative result sharpens what the lab needs to do next — functional and pharmacokinetic assays, not more folding runs.","detailed_analysis":"Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide originally derived from bovine pineal extract, studied over roughly 25 years for geroprotective and telomerase-activating properties. The most compelling recent mechanistic data (Al-Dulaimi et al., 2025) demonstrates dose-dependent telomere elongation in normal human epithelial and fibroblast cells via upregulation of hTERT mRNA, placing telomerase reverse transcriptase (TERT, UniProt O14746) as the primary molecular target of interest. A parallel line of evidence from computational histone-binding studies (Khavinson et al., 2020) suggests the AEDG pharmacophore engages H1 linker histones through its Glu-Asp-Gly residues 2–4, potentially altering chromatin accessibility and downstream TERT transcription. These two proposed mechanisms — direct telomerase engagement and epigenetic chromatin remodeling — are not mutually exclusive, but neither has been resolved to atomic-level detail, which is a foundational limitation for any SAR-driven modification program.\n\nThe modification under study here is conservative by design: L-Ala at position 1 is replaced by its D-configured stereoisomer (D-Ala), preserving the methyl side chain and overall charge profile while inverting backbone chirality at the N-terminus. The pharmacological rationale is textbook — aminopeptidases such as APN/CD13 exhibit strong stereospecificity for L-configured substrates, and D-amino acid substitution at position 1 is a validated strategy across multiple short therapeutic peptides (DSIP, GHK analogs, gonadorelin). Because histone-binding modelling assigns the Ala-1 residue a peripheral rather than contact role, the hypothesis that D-Ala can substitute without disrupting the active pharmacophore is structurally plausible — though unvalidated.\n\nBoltz-2's prediction produced pLDDT 0.34, pTM 0.20, and ipTM 0.16 — all decisively below any threshold for structural inference. This outcome was anticipated by the Researcher agent and is not a surprise: a four-residue flexible peptide simply does not provide enough sequence information for modern structure predictors to resolve a stable conformation. The model reflects genuine intrinsic disorder rather than a misfolded or destabilized variant. Critically, this means the prediction is uninformative in both directions — it neither confirms that D-Ala preserves pharmacophore geometry nor that it disrupts it. Chai-1 agreement data were unavailable, and the Boltz-2 affinity module returned no binding values, so no comparative ΔΔG estimate can be made.\n\nThe heuristic sequence-based profile adds modest context: aggregation propensity is negligible (0.0), stability score is middling (0.4), and the half-life estimate of 15–45 minutes is consistent with aminopeptidase-susceptible short peptides — though this estimate applies to the native L-Ala sequence and does not model the D-Ala effect. BBB penetration score of 0.41 is weakly positive, consistent with the small, polar character of the tetrapeptide.\n\nComparing this fold to DISTILLATION №5 (MOTS-c Met-1 → Norleucine, PROMISING, pLDDT 0.62) is instructive. MOTS-c at 16 residues gave the structure predictor enough sequence context to produce a moderately confident model; the Norleucine substitution's impact on fold geometry could be assessed, even if imperfectly. Epitalon at 4 residues sits below the practical resolution floor of current folding tools. The lesson is that the 'N-terminal protection' strategy is sound across both peptides, but the investigative tool must match the peptide's size regime — folding algorithms for MOTS-c, functional and biophysical assays for Epitalon.\n\nThe literature context amplifies what this DISCARDED fold tells us. There are no published pharmacokinetic data for native Epitalon — the short half-life is an inference, not a measured value. No SAR studies exist on any Epitalon variant. The field has implicitly acknowledged the delivery problem (intranasal routes, ophthalmic formulations) without systematically addressing it at the chemical level. This fold identifies a real unmet need — proteolytic stability data for AEDG — that structure prediction cannot fill but that a simple plasma stability assay could address directly.\n\nTwo biological caveats deserve emphasis. First, the Al-Dulaimi 2025 paper noted that cancer cell lines activate an ALT (alternative lengthening of telomeres) pathway in response to Epitalon — a concern that a stability-enhanced analog with longer systemic exposure would need to address carefully in any safety evaluation. Second, if dominant degradation in vivo proceeds via C-terminal carboxypeptidase cleavage at the Gly-4 terminus or via endopeptidase activity rather than aminopeptidase, D-Ala-1 substitution would provide minimal stability benefit regardless of what any assay shows — pointing to the need for degradation pathway characterization before committing to N-terminal protection as the primary strategy.","executive_summary":"Epitalon D-Ala1 fold: pLDDT 0.34 — structure prediction cannot resolve a 4-residue disordered peptide. Tool limitation, not a failed hypothesis. Plasma stability assays are the right next step.","tweet_draft":"DISTILLATION №6 — discarded.\nEpitalon (AEDG), Ala-1 → D-Ala N-terminal protection.\npLDDT 0.34 | pTM 0.20 — below resolution floor.\n4-residue peptides break structure predictors. Hypothesis intact; wet lab needed.\nIn silico only. alembic.bio","research_brief_markdown":"# DISTILLATION №6 — DISCARDED\n## Epitalon D-Ala1 N-terminal protection to extend plasma half-life\n\n> **Verdict: DISCARDED** — Structure prediction tools are operating below their resolution floor for a 4-residue disordered peptide. The prediction is technically uninformative, not biologically uninformative. The modification hypothesis remains pharmacologically coherent.\n\n---\n\n## Mechanism of action (background)\n\nEpitalon (Ala-Glu-Asp-Gly; AEDG) is a synthetic tetrapeptide geroprotective agent originally derived from bovine pineal extract Epithalamin. Its best-documented molecular activity is **telomerase activation**: recent work (Al-Dulaimi et al., 2025) demonstrates dose-dependent upregulation of hTERT mRNA and enzymatic telomerase activity in normal human epithelial and fibroblast cells, with measurable telomere elongation. A parallel proposed mechanism involves **epigenetic chromatin remodeling** via binding to H1 histone linker domains (residues 2–4, Glu-Asp-Gly, appear to be the primary contact interface per computational modelling; Khavinson et al., 2020), potentially increasing chromatin accessibility and downstream TERT transcription.\n\nBeyond telomerase, Epitalon is reported to exert antioxidant effects, mitochondrial protection, melatonin synthesis modulation, and neuroendocrine regulatory activity — a pleiotropic profile consistent with a peptide whose precise primary receptor has not been identified. Both the direct telomerase hypothesis and the epigenetic chromatin route remain mechanistically unresolved at atomic resolution.\n\n---\n\n## Modification hypothesis (what we tested)\n\nSubstituting the N-terminal **L-Ala-1 with D-Ala** was hypothesized to:\n\n1. **Block aminopeptidase-mediated degradation** — enzymes such as APN/CD13 have strong stereospecificity for L-configured N-terminal residues; a D-amino acid at position 1 is a validated N-terminal protection strategy in short therapeutic peptides (DSIP, GHK analogs, gonadorelin analogues).\n2. **Preserve the active pharmacophore** — D-Ala retains the same methyl side chain as L-Ala, and the histone-binding modelling data suggests residues 2–4 (Glu-Asp-Gly) carry the functional weight, with Ala-1 acting as a spacer. Backbone chirality inversion at position 1 was expected to perturb neither side-chain geometry nor the TERT-interaction surface.\n3. **Extend systemic exposure** for longevity dosing protocols — a peptide with a half-life of minutes provides minimal target tissue exposure; even a modest stability gain could be pharmacologically meaningful.\n\n---\n\n## Why the prediction was uninformative (technical analysis)\n\n| Metric | Value | Interpretation |\n|---|---|---|\n| pLDDT | **0.34** | Far below 0.50 — model is unreliable |\n| pTM | **0.20** | Global topology undefined |\n| ipTM | **0.16** | No interface geometry resolved |\n| Chai-1 agreement | N/A | Unavailable |\n| Affinity module | No values | No binding ΔΔG possible |\n\nBoltz-2 returned metrics that reflect **genuine intrinsic disorder** in a four-residue flexible chain, not a structurally disrupted or misfolded peptide. This outcome was anticipated: modern structure predictors (AlphaFold2, Boltz-2, Chai-1) are trained and validated on proteins and longer peptides with enough sequence context to generate statistical co-evolutionary signal. A tetrapeptide provides no such signal. The tool is operating below its resolution floor.\n\n**The prediction is uninformative in both directions.** It neither confirms that D-Ala-1 preserves pharmacophore geometry, nor that it disrupts it. No structural comparison to native AEDG can be drawn. The DISCARDED verdict is a tool limitation verdict, not a verdict on the biological hypothesis.\n\nContrast this with **DISTILLATION №5** (MOTS-c Met-1 → Norleucine, 16 residues, pLDDT 0.62, PROMISING): MOTS-c provided sufficient sequence length for a moderately confident fold. The N-terminal oxidation-protection strategy was structurally assessable there. For tetrapeptides, folding algorithms cannot substitute for direct experimental measurement.\n\n---\n\n## What this tells us (negative results are data)\n\n**1. Structure prediction is not the right tool for Epitalon SAR.** Any future modification fold on AEDG or closely related tetrapeptides should expect DISCARDED or FAILED verdicts on structural grounds. The lab should not iterate structurally on this peptide — it should pivot to functional and biophysical assays.\n\n**2. The pharmacological rationale remains intact.** Nothing in the prediction contradicts the aminopeptidase-resistance hypothesis. The modification is still worth testing; the fold just cannot adjudicate it.\n\n**3. The degradation pathway is uncharacterized.** If dominant in vivo degradation proceeds via C-terminal carboxypeptidase (Gly-4) or endopeptidase activity rather than N-terminal aminopeptidase cleavage, D-Ala-1 substitution will provide little benefit regardless. The right first experiment is a degradation pathway mapping assay, not a stability comparison between L- and D-Ala variants.\n\n**4. The field has not addressed this problem.** Literature review confirms no published pharmacokinetic data for native Epitalon — the 'minutes' half-life is an inference from general short-peptide degradation kinetics. The entire SAR space for AEDG is a blank map.\n\n---\n\n## Alternative hypotheses to test (avoid the failure mode)\n\n| Approach | Rationale | Tool fit |\n|---|---|---|\n| **Plasma stability assay (native vs D-Ala1)** | Direct measurement of aminopeptidase susceptibility; ground-truth for the modification hypothesis | Wet lab ✓ |\n| **Degradation pathway mapping** (endo vs exo) | Determines whether N-terminal protection is even the right strategy | Wet lab ✓ |\n| **C-terminal amidation** | Protects the Gly-4 terminus from carboxypeptidase; complementary or alternative to D-Ala-1 | Wet lab / synthesis ✓ |\n| **Dual protection: D-Ala1 + C-terminal amide** | Blocks both termini simultaneously; maximally stable AEDG analog | Synthesis ✓ |\n| **PEGylation or lipid conjugation** | Different stability strategy; bypasses stereochemical concerns | Synthesis ✓ |\n| **Molecular dynamics simulation** | More appropriate computational tool than structure prediction for a disordered tetrapeptide; could sample D-Ala conformational ensemble vs native | Computational ✓ |\n| **Histone H1 competitive binding assay** | Tests whether D-Ala-1 alters the AEDG–histone interaction proposed by Khavinson 2020 | Wet lab ✓ |\n\n> ⚠️ **Safety note:** Al-Dulaimi et al. (2025) observed ALT pathway activation in cancer cell lines exposed to Epitalon. Any stability-enhanced analog achieving longer systemic exposure should include cancer cell line safety profiling before advancing in longevity-focused protocols.\n\n---\n\n*All findings are in silico predictions or literature summaries. No wet lab validation has been performed. This is not medical advice.*","structural_caption":"Boltz-2 produced a low-confidence model of the D-Ala1 Epitalon analog with pLDDT 0.34, pTM 0.20, and ipTM 0.16, consistent with an extended, disordered tetrapeptide lacking defined secondary structure. No stable fold or interface geometry could be resolved. The prediction is uninformative regarding whether the D-Ala substitution perturbs the AEDG pharmacophore geometry. Any structural inference about Glu-2/Asp-3/Gly-4 side-chain placement from this model would be unreliable.","key_findings_summary":"Epitalon (AEDG; Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from the bovine pineal gland extract Epithalamin, studied extensively over ~25 years for geroprotective properties. The literature consistently associates Epitalon with telomerase activation and telomere elongation. The most mechanistically detailed recent work (Al-Dulaimi et al., 2025, PMID:40908429) demonstrates dose-dependent telomere length extension in normal human epithelial and fibroblast cells via upregulation of hTERT mRNA and telomerase enzymatic activity, while cancer cell lines appear to use an alternative ALT pathway. These findings establish a direct molecular link between the AEDG pharmacophore and telomerase reverse transcriptase (hTERT) modulation, which is central to the hypothesis under evaluation.\n\nBeyond telomerase, Epitalon exerts broad pleiotropic effects including antioxidant activity, mitochondrial protection, reduction of reactive oxygen species, modulation of melatonin synthesis, epigenetic regulation through histone binding, and neuroendocrine effects (Khavinson et al., 2002; PMID:32019204; PMID:40141333). The 2020 study (PMID:32019204) is notable for proposing a specific epigenetic mechanism whereby AEDG binds H1/3 and H1/6 histone linker domains, potentially altering chromatin accessibility and downstream gene transcription including TERT. This suggests that the intact tetrapeptide sequence engages a defined molecular interaction surface, which raises questions about how even conservative N-terminal modifications might alter binding geometry.\n\nThe hypothesis that substituting L-Ala-1 with D-Ala would confer proteolytic stability is pharmacologically well-grounded for short peptides in general. Tetrapeptides of this size are highly susceptible to aminopeptidase-mediated cleavage from the N-terminus in plasma, and D-amino acid substitution at position 1 is a classical strategy to block this degradation pathway. However, the published literature on Epitalon contains no direct measurements of plasma half-life, no pharmacokinetic studies, and no experimental data on N-terminal modification variants. The review by Araj et al. (2025, PMID:40141333) acknowledges that physico-chemical and structural investigations of Epitalon remain quite limited despite extensive biological study, a gap that directly supports the rationale for this modification work.\n\nStudies in bovine IVP models (Ullah et al., 2025, PMID:39788414) and mouse oocyte aging (Yue et al., 2022, PMID:35413689) reinforce telomerase as the primary functional target in reproductive and somatic cell aging contexts. The intranasal administration route explored in the Sibarov et al. (2002) rat study (PMID:12500171) implies that researchers have already sought routes that bypass first-pass and systemic protease exposure, implicitly acknowledging the degradation problem the D-Ala modification aims to solve. Collectively, the literature strongly supports the biological premise but provides no direct evidence either for or against the stability-preserving effect of N-terminal D-Ala substitution on this specific tetrapeptide."},"structured":{"known_activity":null,"known_binders":null,"candidate_variants":null,"domain_annotations":null,"literature_context":{"pubmed":[{"pmid":"40141333","title":"Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties.","abstract":"Epitalon, also known as Epithalon or Epithalone, is a tetrapeptide, Ala-Glu-Asp-Gly (AEDG), which was synthesized based on the amino acids composition of Epithalamin, a bovine pineal gland extract, prior to its discovery in pineal gland polypeptide complex solution. During the last 25 years, this compound has been extensively studied using in vitro, in vivo, and in silico methods. The results of these studies indicate significant geroprotective and neuroendocrine effects of Epitalone, resulting from its antioxidant, neuro-protective, and antimutagenic effects, originating from both specific and nonspecific mechanisms. Although it has been demonstrated that Epitalon exerts, among other effects, a direct influence on melatonin synthesis, alters the mRNA levels of interleukin-2, modulates the mitogenic activity of murine thymocytes, and enhances the activity of various enzymes, including AChE, BuChE, and telomerase, it remains uncertain whether these are the sole mechanisms of action of this compound. Moreover, despite the considerable volume of research on the biological and pharmacodynamic characteristics of Epitalon, the quantity of physico-chemical and structural investigations of this peptide remains quite limited. This review aims to conclude the most important findings from such studies, thus presenting the current state of knowledge on Epitalon.","authors":["Araj Szymon Kamil","Brzezik Jakub","Mądra-Gackowska Katarzyna","Szeleszczuk Łukasz"],"year":2025,"journal":"International journal of molecular sciences"},{"pmid":"35413689","title":"Epitalon protects against post-ovulatory aging-related damage of mouse oocytes","abstract":"The developmental potential of oocytes decreases with time after ovulation in vivo or in vitro. Epitalon is a synthetic short peptide made of four amino acids (alanine, glutamic acid, aspartic acid, and glycine), based on a natural peptide called epithalamion extracted from the pineal gland. It is a potent antioxidant, comparable to melatonin, that may confer longevity benefits. The current study aims to test the protective effects of Epitalon on the quality of post-ovulatory aging oocytes. Epitalon at 0.1mM was added to the culture medium, and the quality of oocytes was evaluated at 6h, 12h, and 24h of culture. We found that 0.1mM Epitalon reduced intracellular reactive oxygen species. Epitalon treatment significantly decreased frequency of spindle defects and abnormal distribution of cortical granules during aging for 12h and 24h, while increased mitochondrial membrane potential and DNA copy number of mitochondria, thus decreasing apoptosis of oocytes by 24h of in vitro aging. Our results suggest that Epitalon can delay the aging process of oocytes in vitro via modulating mitochondrial activity and ROS levels.","authors":["Yue Xue","Liu Sai-Li","Guo Jia-Ni","Meng Tie-Gang","Zhang Xin-Ran","Li Hong-Xia","Song Chun-Ying","Wang Zhen-Bo","Schatten Heide","Sun Qing-Yuan","Guo Xing-Ping"],"year":2022,"journal":"Aging"},{"pmid":"40908429","title":"Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.","abstract":"Epitalon, a naturally occurring tetrapeptide, is known for its anti-aging effects on mammalian cells. This happens through the induction of telomerase enzyme activity, resulting in the extension of telomere length. A strong link exists between telomere length and aging-related diseases. Therefore, telomeres are considered to be one of the biomarkers of aging, and increasing or maintaining telomere length may contribute to healthy aging and longevity. Epitalon has been the subject of several anti-aging studies however, quantitative data on the biomolecular pathway leading to telomere length increase, hTERT mRNA expression, telomerase enzyme activity, and ALT activation have not been extensively studied in different cell types. In this article, the breast cancer cell lines 21NT, BT474, and normal epithelial and fibroblast cells were treated with epitalon then DNA, RNA, and proteins were extracted. qPCR and Immunofluorescence analysis demonstrated dose-dependent telomere length extension in normal cells through hTERT and telomerase upregulation. In cancer cells, significant telomere length extension also occurred through ALT (Alternative Lengthening of Telomeres) activation. Only a minor increase in ALT activity was observed in Normal cells, thereby showing that it was specific to cancer cells. Our data suggests that epitalon can extend telomere length in normal healthy mammalian cells through the upregulation of hTERT mRNA expression and telomerase enzyme activity.","authors":["Al-Dulaimi Sarah","Thomas Ross","Matta Sheila","Roberts Terry"],"year":2025,"journal":"Biogerontology"},{"pmid":"40493162","title":"The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy.","abstract":"Diabetic retinopathy (DR) is the most common complication of diabetes mellitus and a leading cause of vision loss. Short peptides, such as di-, tri-, and tetrapeptides, have various beneficial activities, including antioxidant, antimicrobial, and anti-inflammatory effects. This study aims to test the hypothesis that the antioxidant effect of the synthetic tetrapeptide AEDG (Ala-Glu-Asp-Gly, Epitalon) improves the delayed healing process associated with hyperglycemia in DR, using a high glucose (HG)-injured human retinal pigment epithelial cell line (ARPE-19). We found that HG exposure delayed wound healing in ARPE-19 cells and increased intracellular levels of reactive oxygen species (ROS), while decreasing antioxidant gene expression. HG also induced epithelial-mesenchymal transition (EMT) and upregulated fibrosis-related genes, suggesting that HG-induced EMT contributes to subretinal fibrosis, the end-stage of eye diseases, including proliferative DR. The antioxidant Epitalon restored impaired wound healing in HG-injured ARPE-19 cells by inhibiting hyperglycemia-induced EMT and fibrosis. These findings support using the antioxidant agent Epitalon as a promising therapeutic strategy for DR to improve retinal wound healing compromised by hyperglycemia. More mechanistic investigations are needed to confirm Epitalon's benefits and safety. Developing ophthalmic forms of Epitalon may enhance its delivery directly to the retina, potentially improving its therapeutic efficacy.","authors":["Gatta Marco","Dovizio Melania","Milillo Cristina","Ruggieri Anna Giulia","Sallese Michele","Antonucci Ivana","Trofimov Aleksandr","Khavinson Vladimir","Trofimova Svetlana","Bruno Annalisa","Ballerini Patrizia"],"year":2025,"journal":"Stem cell reviews and reports"},{"pmid":"39788414","title":"Epitalon-activated telomerase enhance bovine oocyte maturation rate and post-thawed embryo development.","abstract":"Telomerase is highly expressed in oocyte cumulus cells and plays a significant role in follicular development and oocyte maturation. In this study, we hypothesized that in vitro culture conditions may affect telomerase activity during in vitro embryo production (IVP) and that its activation may improve embryo quality. We first examined telomerase protein levels and localization in bovine cumulus-oocyte complexes via immunofluorescence assays. The results showed that healthy cumulus-oocyte complexes have the nuclear localization of the telomerase while the degraded cumulus-oocyte complex had reduced telomerase levels and that telomerase was localized in the cytoplasm. We activated telomerase via Epitalon, a tetrapeptide with the amino acid sequence Ala-Glut-Asp-Gly. We observed a significant improvement in the oocyte maturation rate compared with the control group (p < 0.05). Furthermore, telomerase activity was significantly compromised in post-thawed embryos, and Epitalon treatment significantly improved blastocyst hatching rate and implantation potential (p < 0.05). Moreover, we performed qPCR, reactive oxygen species, and JC-1 (ΔΨm) assays to evaluate the effect of Epitalon on the health of in vitro mature oocytes, cumulus cells, and post-thawed blastocysts, and the result showed that Epitalon highly enhances the quality and health of the oocyte, cumulus cell, and post-thawed blastocyst. Our results suggest that telomerase activation via Epitalon improves bovine in vitro embryo production.","authors":["Ullah Safeer","Haider Zaheer","Perera Chalani Dilshani","Lee Su Hyeon","Idrees Muhammad","Park Song","Kong Il-Keun"],"year":2025,"journal":"Life sciences"},{"pmid":"12374906","title":"Peptides and Ageing.","abstract":"A technology has been developed for manufacturing of biologically active complex peptide preparations from extracts of different tissues. In particular, the pineal preparation (Epithalamin) augments the in vitro outgrowth of explants from the pineal gland but not from other tissues, the latter being stimulated by peptide preparations from respective tissues. Epithalamin increases melatonin production by the pineal gland of rats, improves immunological parameters in rats and mice, produces anticarcinogenic effects in different experimental models, stimulates antioxidant defenses, and restores the reproductive function in old rats. These effects are combined in the ability of Epithalamin to increase the lifespan in rats, mice, and fruit flies. Many of these effects are reproduced in clinical trials, which have demonstrated the geroprotector activity of Epithalamin in humans. Among the effects of the thymic preparation Thymalin, those related to its ability to stimulate immunity are the most prominent. This ability is associated with anticarcinogenic and geroprotector activities. Clinical trials of the peptide preparations obtained from other organs including the prostate, the cerebral cortex, and the eye retina, have demonstrated beneficial effects reflected by the improvement of the conditions of respective organs. Based on the data about the amino acid compositions of the peptide preparations, novel principles of the design of biologically active short peptides possessing tissue-specific activities has been developed. Dipeptides specific for the thymus and tetrapeptides specific for the heart, liver, brain cortex, and pineal glands stimulate the in vitro outgrowth of explants of respective organs. Interestingly, for eye retina and the pineal gland, a common tetrapeptide Ala-Glu-Asp-Gly (Epitalon) has been designed, probably reflecting the common embryonal origin of these two organs. Epitalon reproduces the effects of Epithalamin including those related to its geroprotector activity. In particular, Epitalon increases the lifespan of mice and fruit flies and restores the circadian rhythms of melatonin and cortisol production in old rhesus monkeys. At the same time, Epitalon prolongs the functional integrity of the eye retina in Campbell rats with hereditary Retinitis Pigmentosa and improves the visual functions in patients with pigmental retinal degeneration. Changes in gene expression were observed to be produced by the short peptide preparations. Therefore, the effects of Epitalon are suggested to be mediated by transcriptional machinery common for the pineal gland and the retina and, probably, for regulation of melatonin production in fruit flies. Based on three decades of studies of the peptide preparations, the peptide theory of ageing has been put forward. According this theory, ageing is an evolutionary determined biological process of changes in gene expression resulting in impaired synthesis of regulatory and tissue-specific peptides in organs and tissues, which provokes their structural and functional changes and the development of diseases. Correspondingly, correction of such disorders by means of stimulation of peptide production in the organism or through their delivery can promote the normalisation of disturbed body functions.","authors":["Khavinson Vladimir Kh"],"year":2002,"journal":"Neuro endocrinology letters"},{"pmid":"12500171","title":"Epitalon influences pineal secretion in stress-exposed rats in the daytime.","abstract":"OBJECTIVES: The content of C-Fos protein was tested in rat pinealocytes in the norm and stress and in case of intranasal administration of Epitalon (Ala-Glu-Asp-Gly), which regulated pineal secretion processes, presumably, via protooncogenes.\n\nSETTING: Intact and osmotic-stress-exposed rats were used for the immunohistochemical detection of C-Fos protein. All animals were intranasally administered with Epitalon, the last infusion made in two hours before the biopsy. Simultaneously, light microscopy of the pineal parenchyma was performed in all groups of animals.\n\nRESULTS: A slight but significant C-Fos increase was observed only in stress-exposed pinealocytes of rats after intranasal Epitalon infusions. C-Fos was irregularly distributed throughout pineal cells. In stress, the clusters of 5 10 cells containing C-Fos in their cytoplasm were detected. The dilation of capillaries and pericapillary space induced by an osmotic stress was partially reduced by the intranasal infusions of Epitalon.\n\nCONCLUSIONS: Tetrapeptide Epitalon is synthesised on the basis of the amino acid composition of pineal peptide extract Epithalamin. Epitalon modulates pineal secretion only under a stress impact but never in the norm. It prevents osmotic-stress-induced pathologic changes in the pineal parenchyma structure. Besides, the physiological activity of Epitalon seems to be mediated by the activation of protooncogenes in pinealocytes.","authors":["Sibarov Dmitry A","Kovalenko Rimma I","Malinin Vladimir V","Khavinson Vladimir Kh"],"year":2002,"journal":"Neuro endocrinology letters"},{"pmid":"32019204","title":"AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism.","abstract":"It was shown that AEDG peptide (Ala-Glu-Asp-Gly, Epitalon) regulates the function of the pineal gland, the retina, and the brain. AEDG peptide increases longevity in animals and decreases experimental cancerogenesis. AEDG peptide induces neuronal cell differentiation in retinal and human periodontal ligament stem cells. The aim of the study was to investigate the influence of AEDG peptide on neurogenic differentiation gene expression and protein synthesis in human gingival mesenchymal stem cells, and to suggest the basis for the epigenetic mechanism of this process. AEDG peptide increased the synthesis of neurogenic differentiation markers: Nestin, GAP43, β Tubulin III, Doublecortin in hGMSCs. AEDG peptide increased Nestin, GAP43, β Tubulin III and Doublecortin mRNA expression by 1.6-1.8 times in hGMSCs. Molecular modelling method showed, that AEDG peptide preferably binds with H1/6 and H1/3 histones in His-Pro-Ser-Tyr-Met-Ala-His-Pro-Ala-Arg-Lys and Tyr-Arg-Lys-Thr-Gln sites, which interact with DNA. These results correspond to previous experimental data. AEDG peptide and histones H1/3, H1/6 binding may be one of the mechanisms which provides an increase of Nestin, GAP43, β Tubulin III, and Doublecortin neuronal differentiation gene transcription. AEDG peptide can epigenetically regulate neuronal differentiation gene expression and protein synthesis in human stem cells.","authors":["Khavinson Vladimir","Diomede Francesca","Mironova Ekaterina","Linkova Natalia","Trofimova Svetlana","Trubiani Oriana","Caputi Sergio","Sinjari Bruna"],"year":2020,"journal":"Molecules (Basel, Switzerland)"},{"pmid":"41240216","title":"Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.","abstract":"","authors":["Al-Dulaimi Sarah","Thomas Ross","Matta Sheila","Roberts Terry"],"year":2025,"journal":"Biogerontology"}],"biorxiv":[{"pmid":"","doi":"10.21203/rs.3.rs-7066545/v1","title":"Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity","abstract":"<title>Abstract</title>  <p>Epitalon, a naturally occurring tetrapeptide, is known for its anti-aging effects on mammalian cells. This happens through the induction of telomerase enzyme activity, resulting in the extension of telomere length. A strong link exists between telomere length and aging-related diseases. Therefore, telomeres are considered to be one of the biomarkers of aging, and increasing or maintaining telomere lengths may contribute to healthy aging and longevity. Epitalon has been the subject of several anti-aging studies however, quantitative data on the biomolecular pathway leading to telomere length increase, <italic>hTERT mRNA </italic>expression, telomerase enzyme activity, and ALT activation have not been extensively studied in different cell types. In this article, the breast cancer cell lines 21NT, BT474, and normal epithelial and fibroblast cells were treated with epitalon then DNA, RNA, and proteins were extracted. qPCR and Immunofluorescence analysis demonstrated dose-dependent telomere length extension in normal cells through <italic>hTERT</italic>and telomerase upregulation. In cancer cells, significant telomere length extension also occurred through ALT (Alternative Lengthening of Telomeres) activation. Only a minor increase in ALT activity was observed in Normal cells, thereby showing that it was specific to cancer cells. Our data suggests that Epitalon can extend telomere length in normal healthy mammalian cells through the upregulation of <italic>hTERT</italic> mRNA expression and telomerase enzyme activity.</p>","authors":["Al-dulaimi S","Thomas R","Matta S","Roberts T."],"year":2025,"journal":"PPR","source":"PPR","preprint":true}],"preprints":[{"pmid":"","doi":"10.21203/rs.3.rs-7066545/v1","title":"Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity","abstract":"<title>Abstract</title>  <p>Epitalon, a naturally occurring tetrapeptide, is known for its anti-aging effects on mammalian cells. This happens through the induction of telomerase enzyme activity, resulting in the extension of telomere length. A strong link exists between telomere length and aging-related diseases. Therefore, telomeres are considered to be one of the biomarkers of aging, and increasing or maintaining telomere lengths may contribute to healthy aging and longevity. Epitalon has been the subject of several anti-aging studies however, quantitative data on the biomolecular pathway leading to telomere length increase, <italic>hTERT mRNA </italic>expression, telomerase enzyme activity, and ALT activation have not been extensively studied in different cell types. In this article, the breast cancer cell lines 21NT, BT474, and normal epithelial and fibroblast cells were treated with epitalon then DNA, RNA, and proteins were extracted. qPCR and Immunofluorescence analysis demonstrated dose-dependent telomere length extension in normal cells through <italic>hTERT</italic>and telomerase upregulation. In cancer cells, significant telomere length extension also occurred through ALT (Alternative Lengthening of Telomeres) activation. Only a minor increase in ALT activity was observed in Normal cells, thereby showing that it was specific to cancer cells. Our data suggests that Epitalon can extend telomere length in normal healthy mammalian cells through the upregulation of <italic>hTERT</italic> mRNA expression and telomerase enzyme activity.</p>","authors":["Al-dulaimi S","Thomas R","Matta S","Roberts T."],"year":2025,"journal":"PPR","source":"PPR","preprint":true}],"consensus_view":"The literature consensus is that Epitalon (AEDG) activates telomerase in mammalian cells, elevates hTERT mRNA expression, extends telomere length, and exerts broad antioxidant and geroprotective effects. These findings are reasonably consistent across in vitro human cell line data (2025), bovine IVP models (2025), mouse oocyte studies (2022), and rat in vivo work (2002). The consensus also holds that the intact AEDG sequence constitutes the active pharmacophore. However, there is no consensus—or indeed any published data—on the pharmacokinetics, plasma half-life, or proteolytic stability of native Epitalon, and no studies have examined any stereochemical or chemical modifications to the peptide backbone. The field has not systematically addressed the delivery problem that the D-Ala modification targets.","knowledge_gaps":"Critical gaps include: (1) No published plasma half-life or pharmacokinetic data for native Epitalon in any species—the 'minutes' half-life estimate is an inference from general short-peptide degradation kinetics, not direct measurement. (2) No structure-activity relationship (SAR) studies have examined modifications to the AEDG backbone; it is unknown whether even the conservative L→D-Ala change at position 1 alters histone binding, receptor engagement, or cellular uptake. (3) The precise molecular receptor or binding partner of Epitalon that leads to hTERT upregulation has not been identified; it may be an extracellular receptor, an intracellular target following internalization, or indirect (epigenetic via histone binding). This mechanistic gap makes it impossible to predict from first principles whether D-Ala-1 will disrupt the relevant interaction. (4) No in vivo pharmacodynamic studies link systemic exposure levels to telomerase activation magnitude, so it is unclear what minimum exposure duration is required for efficacy. (5) Bioavailability and tissue distribution data are absent, making it difficult to model whether improved plasma stability would translate to greater target tissue exposure.","supporting_evidence":"The primary supporting evidence for the hypothesis is indirect but structurally sound: (1) Epitalon's telomerase-activating activity is well-documented (PMID:40908429; PMID:39788414), establishing hTERT as a valid target. (2) The tetrapeptide is extremely short; aminopeptidase cleavage of the N-terminal Ala-Glu bond is a predictable and dominant degradation pathway for such peptides in plasma, and D-amino acid substitution at the N-terminus is a validated strategy to block this in other peptide contexts. (3) The histone-binding molecular modelling data (PMID:32019204) shows AEDG interacts via Glu-Asp-Gly residues 2–4 at the binding interface, suggesting position 1 (Ala) may be more of a structural spacer than a critical pharmacophoric element, lending plausibility to the idea that D-Ala can substitute without losing activity. (4) The use of intranasal delivery (PMID:12500171) and the acknowledged need for ophthalmic formulations (PMID:40493162) reflect recognition in the field that systemic delivery of native Epitalon is problematic, supporting the premise that stability enhancement is pharmacologically meaningful.","challenging_evidence":"Several considerations complicate or challenge the hypothesis: (1) The histone-binding data (PMID:32019204) is computational (molecular modelling only, no crystallography or mutagenesis validation), so the conclusion that Ala-1 is dispensable for binding is uncertain. If Ala-1 participates in a conformational anchor or turn structure that is disrupted by the D-stereocenter, activity could be impaired. (2) The Al-Dulaimi et al. 2025 paper (PMID:40908429) used Epitalon in cancer cell lines and found ALT pathway activation—an undesirable oncogenic concern that any stability-enhanced analog would share or potentially amplify if longer systemic exposure is achieved. This raises a safety consideration for longevity applications. (3) There are no published aminopeptidase kinetic data for AEDG specifically; if the rate-limiting degradation in vivo is C-terminal carboxypeptidase cleavage (Gly terminus) or endopeptidase activity rather than aminopeptidase, D-Ala-1 substitution would provide minimal benefit. (4) The literature quality is moderate at best: most mechanistic studies are from a single research group (Khavinson and collaborators), cell-line studies lack rigorous controls for non-specific effects, and no randomized human clinical pharmacokinetic data exist. The 2025 Al-Dulaimi publication required a correction (PMID:41240216), signaling potential methodological issues. (5) The 'longevity dosing' clinical application is entirely speculative—no human efficacy data exist for Epitalon at any dose or route, making the translational claim that improved stability will benefit longevity protocols unsupported by clinical evidence."},"caveats":["in silico prediction only — requires wet lab validation","single-run prediction (not ensembled)","predicted properties may not reflect real-world biological behavior","this is research, not medical advice","pLDDT 0.34 is below the minimum threshold for structural inference — no backbone or side-chain geometry should be interpreted from this model","four-residue tetrapeptides are below the practical resolution floor of current structure prediction tools; DISCARDED verdict reflects tool limitation, not biological failure","half-life estimate (15–45 min) is a heuristic sequence-based inference for native AEDG and does not model the effect of D-Ala-1 substitution on proteolytic stability","no published pharmacokinetic data exist for native Epitalon; the 'short half-life' premise is an inference from general short-peptide degradation kinetics, not direct measurement","dominant degradation pathway for Epitalon in vivo (aminopeptidase vs carboxypeptidase vs endopeptidase) has not been characterized; D-Ala-1 protection may be ineffective if N-terminal cleavage is not rate-limiting","cancer cell ALT pathway activation reported for native Epitalon (Al-Dulaimi et al., 2025); stability-enhanced analogs should include oncological safety profiling"],"works_cited":[{"pmid_or_doi":"40908429","title":"Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity","year":2025,"relevance":"Provides the most direct quantitative evidence that Epitalon upregulates hTERT mRNA and telomerase enzymatic activity in normal human cells, directly supporting the target (TERT) specified in the hypothesis."},{"pmid_or_doi":"40141333","title":"Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties","year":2025,"relevance":"Comprehensive review confirming telomerase enhancement as a key mechanism and explicitly noting that physico-chemical/structural studies of Epitalon are sparse, underscoring the gap that motivates stability-focused modifications."},{"pmid_or_doi":"32019204","title":"AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism","year":2020,"relevance":"Molecular modelling identifies specific histone-binding sites for AEDG, suggesting the intact pharmacophore engages a defined interaction surface; relevant to assessing whether N-terminal D-Ala substitution could perturb binding geometry."},{"pmid_or_doi":"39788414","title":"Epitalon-activated telomerase enhance bovine oocyte maturation rate and post-thawed embryo development","year":2025,"relevance":"Demonstrates telomerase activation by Epitalon in a physiologically relevant IVP model and confirms TERT as a functional target across mammalian systems, supporting the generalizability of the hypothesis."},{"pmid_or_doi":"35413689","title":"Epitalon protects against post-ovulatory aging-related damage of mouse oocytes","year":2022,"relevance":"Shows Epitalon's protective effects are mediated via mitochondrial activity and ROS reduction in addition to telomerase, indicating the peptide has multiple downstream effectors that a stability-enhanced analog should also preserve."},{"pmid_or_doi":"12500171","title":"Epitalon influences pineal secretion in stress-exposed rats in the daytime","year":2002,"relevance":"Use of intranasal administration route implicitly acknowledges systemic degradation challenges for this short peptide, indirectly supporting the rationale for improving plasma stability."},{"pmid_or_doi":"12374906","title":"Peptides and Ageing","year":2002,"relevance":"Early foundational work by Khavinson establishing geroprotective effects of Epithalamin-derived peptides including lifespan extension, providing historical context for Epitalon's biological targets."},{"pmid_or_doi":"40493162","title":"The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy","year":2025,"relevance":"Demonstrates AEDG pharmacophore activity in an in vitro cellular model, supporting the concept that the four-residue sequence is sufficient for bioactivity and that preserving this sequence in a D-Ala analog should retain function."},{"pmid_or_doi":"10.21203/rs.3.rs-7066545/v1","title":"Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity (preprint)","year":2025,"relevance":"Preprint version of Al-Dulaimi et al. providing additional methodological detail on hTERT upregulation; now published as PMID:40908429, lending peer-review confidence to the telomerase mechanism findings."}]},"onchain":{"hash":"2aZa8hEF3nU8tJKUzDKuJVhrtpCQYkKu2NwhJopxRcF5RwHq4J237FHY4KLwdra1wfWntjmifXjTg6EErHCgWAic","signature":"2aZa8hEF3nU8tJKUzDKuJVhrtpCQYkKu2NwhJopxRcF5RwHq4J237FHY4KLwdra1wfWntjmifXjTg6EErHCgWAic","data_hash":"91c969e59ef2b5c136af70134c7b871736b8d7da0ce7036b3f3a0197fc4d8bb3","logged_at":"2026-05-02T14:00:28.902884+00:00","explorer_url":"https://solscan.io/tx/2aZa8hEF3nU8tJKUzDKuJVhrtpCQYkKu2NwhJopxRcF5RwHq4J237FHY4KLwdra1wfWntjmifXjTg6EErHCgWAic"},"ipfs_hash":null,"created_at":"2026-05-02T13:52:47.969092+00:00","updated_at":"2026-05-02T14:00:28.906395+00:00"}